|
Rural populations, still representing close to half of China’s total population, struggle to access drugs, given limitations in infrastructure, facilities and healthcare professionals ranging from surgeons, to general practitioners, to nurses and lab assistants.
Countless patients still ingest or inject drugs that have poor quality standards and that therefore will lead to poor medical outcomes. The landscape of manufacturers, more than 4,000, is so fragmented that it is difficult to identify quality ones, worthy of trust. Real efforts to raise manufacturing standards are underway, but will take time to have broader impact. As of 2015, over half of the world’s most important drugs launched after 2008, as measured by global sales, where not yet approved in China. Several of those included breakthrough treatments, representing a new standard of care with significant impact on patient outcomes, including for diseases such as certain types of cancer. The situation is so acute that travel agencies have popped up to offer medical tourism services to Chinese patients looking for those drugs in Hong Kong, Macau, or even the US. Rapid new drug development has becoming a public health issue affect tens of millions of Chinese patients. SAHNT foundation partnered with pharmaceutical companies, investors and clinical trial service providers together, hence build a global drug develop network to speed up the whole process significantly. |
cancerA new report estimates there were 4.3 million new cancer cases and more than 2.8 million cancer deaths in China in 2015, with lung cancer the most common cancer and the leading cause of cancer death in China.
|
rare diseaseChina is still in the early stages of enacting policies related to rare diseases and regulation of much needed orphan drugs. In China, there is currently no specific nationwide legislation for orphan drugs in China.
|
partnershipPartnered with Shifield International Group to build a global network and to explore innovative strategies to speed up the new drug approval process in China.
|
Shifield Group
